Jeff Jones
Stock Analyst at Oppenheimer
(1.99)
# 3,076
Out of 5,067 analysts
95
Total ratings
30.59%
Success rate
-2.72%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Reiterates: Outperform | $50 → $57 | $25.40 | +124.41% | 2 | Nov 14, 2025 | |
| VTYX Ventyx Biosciences | Maintains: Outperform | $9 → $14 | $9.43 | +48.46% | 11 | Oct 27, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $53 → $63 | $66.04 | -4.60% | 6 | Oct 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $2.53 | +888.14% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $12.01 | +341.30% | 10 | Aug 6, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $20.35 | +116.22% | 3 | Jun 24, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $7.30 | +242.47% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $3.63 | +368.32% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $8.57 | +98.37% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $39.35 | +118.55% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $4.14 | +334.78% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.86 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $2.09 | +665.55% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.55 | +2,803.23% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $17.71 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.09 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.79 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.32 | +1,036.36% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $0.43 | +17,456.18% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $5.18 | +21,135.52% | 2 | Nov 17, 2022 |
Pelthos Therapeutics
Nov 14, 2025
Reiterates: Outperform
Price Target: $50 → $57
Current: $25.40
Upside: +124.41%
Ventyx Biosciences
Oct 27, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $9.43
Upside: +48.46%
Kymera Therapeutics
Oct 1, 2025
Maintains: Outperform
Price Target: $53 → $63
Current: $66.04
Upside: -4.60%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $2.53
Upside: +888.14%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $12.01
Upside: +341.30%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $20.35
Upside: +116.22%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $7.30
Upside: +242.47%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $3.63
Upside: +368.32%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $8.57
Upside: +98.37%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $39.35
Upside: +118.55%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $4.14
Upside: +334.78%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $2.86
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $2.09
Upside: +665.55%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.55
Upside: +2,803.23%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $17.71
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.09
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $4.79
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.32
Upside: +1,036.36%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $0.43
Upside: +17,456.18%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $5.18
Upside: +21,135.52%